Randomized trial · people
Tirzepatide plus apitegromab: 1.9 kg less lean mass loss in EMBRAZE
Checked against the paper Randomized trialPublished by PepVault
The takeaway
Lean mass is lost along with fat during tirzepatide weight loss, and this early trial found an experimental add-on antibody reduced that lean mass loss without changing total weight loss.
- Kind
- Randomized trial
- Studied in
- People
- Number studied
- 102
- Published
- 2026
- Journal
- Nat Med
What they tested
The team tested whether adding apitegromab, an experimental antibody that blocks myostatin activation, to tirzepatide would limit the lean mass people lose as they lose weight.
How the study was done
A randomized, double-blind, placebo-controlled phase 2 trial in 102 adults with overweight or obesity. Everyone took tirzepatide, and they were split evenly to add either apitegromab (10 mg kg-1) or a placebo, a dummy treatment, for 24 weeks.

Model. Individual results vary.
What they found
At week 24, the apitegromab group lost 1.9 kg less lean mass than the placebo group (80% CI 1.2-2.7, P = 0.001). Total body weight loss was similar between the groups. The team described this as 54.9% retention of lean mass compared with placebo. Side effects were about as common in both groups: 39 of 51 (76%) on apitegromab and 36 of 51 (71%) on placebo, and serious side effects occurred in 1 of 51 people in each group.
What it doesn’t show
This was a small, 24-week phase 2 trial meant as an early test of the idea. The results are about lean mass, so effects on strength, physical function or longer-term health aren't shown.
The paper
Pratley et al. Apitegromab for lean mass preservation during tirzepatide-induced weight loss: a randomized, double-blind, placebo-controlled phase 2 trial. Nat Med. 2026.
The compound
More studies on Tirzepatide
- Dulaglutide: switching to tirzepatide beat dose escalation on HbA1cRandomized trial · people · 2025
- Tirzepatide: up to 19.7% weight loss at 176 weeks in SURMOUNT-1Randomized trial · people · 2025
- Tirzepatide: about 75% of weight lost was fat in SURMOUNT-1Randomized trial · people · 2025
- Tirzepatide: most reached a weight plateau by week 72 in SURMOUNT-1Randomized trial · people · 2025
- Tirzepatide: 20.2% weight loss vs 13.7% on semaglutide at 72 weeksRandomized trial · people · 2025
- Tirzepatide: up to 17.5% weight loss at 52 weeks in SURMOUNT-CNRandomized trial · people · 2024
- Every study on Tirzepatide
Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.